Related Experiment Videos
Global gene expression in a type 2 Gaucher disease brain.
Rachel Myerowitz1, Hiroki Mizukami, Kristine L Richardson
1Department of Biology, St. Mary's College of Maryland, St. Mary's City, MD 20686, USA.
Molecular Genetics and Metabolism
|December 14, 2004
Summary
Gaucher disease, a sphingolipidosis, involves glucocerebroside accumulation. Gene expression profiling in a type 2 Gaucher brain revealed altered profiles and elevated gamma-synuclein, offering insights into neurodegeneration.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Gaucher disease is a sphingolipidosis caused by deficient glucocerebrosidase activity, leading to glucosylceramide accumulation.
- Types 2 and 3 Gaucher disease exhibit severe neurodegeneration.
- Understanding gene expression in Gaucher disease is crucial for elucidating neurodegeneration mechanisms.
Purpose of the Study:
- To characterize gene expression profiles in the brain of a type 2 Gaucher disease patient.
- To identify molecular differences in neurodegeneration compared to normal brains and other sphingolipidoses.
Main Methods:
- Serial Analysis of Gene Expression (SAGE) was employed.
- Gene expression profiles from a type 2 Gaucher brain were analyzed.
- Comparisons were made with normal control brains and brains from Tay-Sachs and Sandhoff patients.
Main Results:
- The gene expression profile of the type 2 Gaucher brain was significantly altered compared to controls.
- Distinct differences were observed in genes related to macrophage activation when compared to Tay-Sachs and Sandhoff patients.
- Gamma-synuclein, implicated in other neurodegenerative disorders, was found to be elevated.
Conclusions:
- Gene expression profiling provides insights into the molecular pathology of Gaucher disease neurodegeneration.
- Elevated gamma-synuclein in Gaucher disease warrants further investigation.
- Macrophage activation pathways may play a differential role in Gaucher disease neurodegeneration compared to other sphingolipidoses.